Skip to content

Tectonic Therapeutics TECX Change in Accrued Liabilities

Change in Accrued Liabilities at other companies

Septerna, Inc. logo
Septerna, Inc.SEPN
-$3.53M-2.5%
Regenxbio logo
RegenxbioRGNX
-$16.73M-15.5%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$683K-84.6%
Opko Health logo
Opko HealthOPK
-$8.16M+57.9%
Ginkgo Bioworks logo
Ginkgo BioworksDNA
-$11.6M-231%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
-$5.91M-43.5%

Other financials

Income statement

See full
Operating income-$27.3M-49.2%
Net income-$25.2M-58.7%
EPS (diluted)-$1.34-44.1%

Balance sheet

See full
Cash & equivalents$236.9M-22.8%
Total debt$4.9M+86.1%
Total equity$230.4M-23.5%
Total assets$246.6M-21.7%

Cash flow

See full
Operating cash flow-$18.4M-40.7%
CapEx$19.0K-29.6%
Free cash flow-$18.4M-40.6%

Valuation

See full
Market cap$585.51M+58.3%
Enterprise value$353.51M+438%

Returns & leverage

See full
Return on equity-31.4%
Debt / equity0.0×
Current ratio18.5×-4.4×

Where this comes from

Reported directly by Tectonic Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.

The official record: Tectonic Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tectonic Therapeutics's change in accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tectonic Therapeutics's change in accrued liabilities?
Tectonic Therapeutics (TECX) reported change in accrued liabilities of $1.63M in Q1 2026.
How has Tectonic Therapeutics's change in accrued liabilities changed year-over-year?
Tectonic Therapeutics's change in accrued liabilities increased by 147.8% year-over-year, from -$3.42M to $1.63M.
What does change in accrued liabilities mean?
Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.